Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Twist Bioscience Corporation (TWST)

152.78 -20.67 (-11.92%)
At close: October 30 at 4:00:01 PM EDT
155.77 +2.99 (+1.96%)
Pre-Market: 7:30:52 AM EST
Trade TWST on Coinbase
Chart Range Bar
Loading chart for TWST
  • Previous Close 173.45
  • Open 161.39
  • Bid 118.44 x 200
  • Ask 189.93 x 200
  • Day's Range 148.00 - 167.27
  • 52 Week Range 23.30 - 219.71
  • Volume 3,399,915
  • Avg. Volume 2,328,978
  • Market Cap (intraday) 10.129B
  • Beta (5Y Monthly) 2.22
  • PE Ratio (TTM) --
  • EPS (TTM) -2.23
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 168.25
  • Zacks Rating Neutral

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

www.twistbioscience.com

979

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TWST
381.65%
S&P 500 (^GSPC)
10.73%

1-Year Return

TWST
390.15%
S&P 500 (^GSPC)
11.11%

3-Year Return

TWST
913.13%
S&P 500 (^GSPC)
81.91%

5-Year Return

TWST
28.60%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 118.38M
Earnings -35.05M
Profit Margin -29.61%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
-38.0%
-36.0%
-34.0%
-32.0%
-30.0%
-28.0%

Analyst Insights

View More

Analyst Price Targets

45.00 Low
168.25 Average
152.78 Current
215.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/13/2026
Analyst TD Cowen
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 115 -> 190

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    10.13B

  • Enterprise Value

    10.06B

  • Trailing P/E

    --

  • Forward P/E

    483.10

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    21.61

  • Price/Book (mrq)

    21.49

  • Enterprise Value/Revenue

    23.30

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.66%

  • Return on Assets (ttm)

    -13.09%

  • Return on Equity (ttm)

    -29.59%

  • Revenue (ttm)

    431.8M

  • Net Income Avi to Common (ttm)

    -136.72M

  • Diluted EPS (ttm)

    -2.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    166.84M

  • Total Debt/Equity (mrq)

    24.36%

  • Levered Free Cash Flow (ttm)

    -64.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

152.78 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 10/06/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 07/14/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/15/2025

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: